ÂÒÂ×Ðã

ÂÒÂ×Ðã scientists gathered at the symposium to discuss their research in advanced therapies, from laboratories into commercialisation. The extensive pipelines unveil a huge potential for collaborations with research and commercial partners to bring life-changing impact to patients.

Photo 1: Professor Geraint Rees, Vice-Provost (Research, Innovation & Global Engagement) at ÂÒÂ×Ðã, spoke at the ÂÒÂ×Ðã Advanced Therapies Symposium to highlight the unique ecosystem and partnerships built for ÂÒÂ×Ðã's ATMP success.

On 24 April, ÂÒÂ×Ðã launched its first Advanced Therapies Symposium that attracted over 250 attendees from ÂÒÂ×Ðã and beyond, including ÂÒÂ×Ðã scientists, research and clinical collaborators, funding entities, and healthcare industry leaders specialising in Advanced Therapy Medicinal Product (ATMP) research and developments.

The ATMP report, released during the symposium, lays out the ÂÒÂ×Ðã’s key statistics in its ATMP research and commercialisation projects which represents one of the world’s largest development pipelines for Advanced Therapy Medicinal Products (ATMP). It demonstrates the extensive experimental and clinical expertise spanning across disciplines, highlighting specialisms in Rare Diseases, Ophthalmology, Haematology/Oncology, Neurology, and Immunology.

Key figures from the report include:

• 100+ projects in development, from discovery, clinical trials through to market launch.
• Close to £80M in public funding to support the current active projects spanning preclinical stage and Phase I/II trials.
• One treatment for haemophilia A, ¸é´Ç³¦³Ù²¹±¹¾±²¹²Ôâ„¢, already licenced in the U.S and EU through ÂÒÂ×Ðã’s partner Biomarin.
• 54% of the UK’s entire ATMP academically sponsored clinical trials are conducted via ÂÒÂ×Ðã partner hospitals.
• 43% of the UK’s commercial sponsored trials are delivered by ÂÒÂ×Ðã partner hospitals.

The figures underline not just the research excellence of these complex therapies at ÂÒÂ×Ðã, but also its leading position in moving the advanced therapy field out of the research laboratories into commercialisation, with approved drugs being delivered to patients.

Over the past 10 years, ÂÒÂ×Ðã has successfully spun out twelve advanced therapy companies, which collectively have received in excess of £2Bn of external investment, with five companies having IPO’d.

At the symposium, ÂÒÂ×Ðã scientists discussed their expertise in advanced therapies, with a focus on ÂÒÂ×Ðã's early-stage research and clinical experience, alongside presentations on successful case studies. Panel discussions on industry and venture capital (VC) investments in spinouts, as well as clinical experience in delivering these complex therapies, inspired immense knowledge exchange on and off the stage.

Chairing the panel discussion on industry and VC investments, Dr. Anne Lane, CEO of ÂÒÂ×Ðã Business (ÂÒÂ×ÐãB), said, "The coordinated support between ÂÒÂ×Ðã, ÂÒÂ×ÐãB, and its partner hospitals—from science-trained business managers, translational research experts, and clinical facilities and units—creates a unique position for ÂÒÂ×Ðã to make every step towards successful commercialisation, helping to de-risk projects and maximise venture capital investment."Ìý

Professor Geraint Rees, Vice-Provost (Research, Innovation & Global Engagement) at ÂÒÂ×Ðã, added in his closing remarks, "It is the precious ecosystem we have created over the years and partnerships with various stakeholders – from patients, hospitals, funding, research, and investment partners – that make ÂÒÂ×Ðã a global leader in advanced therapies. Our R&D and clinical pipelines are supported by unparalleled commercial pipelines along the translational pathway, enabling us to make a real impact on individual lives."Ìý

The symposium is organised by the ÂÒÂ×Ðã Translational Research Office (TRO) and the Therapeutic Innovation Networks (TINs), and chaired by Professor Simon Waddington, Professor of Gene Therapy and Maternal & Fetal Medicine at ÂÒÂ×Ðã, who leads the Cell and Gene Therapy network under the TINs.

Photo 2: Professor Simon Waddington, Professor of Gene Therapy and Maternal & Fetal Medicine at ÂÒÂ×Ðã, kicked off ÂÒÂ×Ðã’s first Advanced Therapies Symposium.

Photo 3:ÌýDr. Anne Lane, CEO of ÂÒÂ×Ðã Business, led the panel discussion on industry and venture capital investments in spinouts, joined by Professor Emma Morris (ÂÒÂ×Ðã), Professor Bobby Gaspar (ÂÒÂ×Ðã), Dr. Richard Fagan (ÂÒÂ×ÐãB), and Dr. Elisa Petris (Syncona Investment Management Ltd).

Photo 4:ÌýProfessor Dimitri Michael Kullmann, Professor of Clinical and Experimental Epilepsy at ÂÒÂ×Ðã Queen Square Institute of Neurology, led the panel discussion on ÂÒÂ×Ðã’s clinicians' experience, joined by Professors Amit Nathwani, Sarah Tabrizi, Manju Kurian, and Claire Booth.

Photo 5a-b:ÌýÂÒÂ×Ðã early career researchers (ECRs) across research disciplines showcased their research posters at the event and exchanged ideas with the attendees.

Photo 6a-b:ÌýThe ÂÒÂ×Ðã Advanced Therapies Symposium presented unprecedented networking opportunities between ÂÒÂ×Ðã scientists and its research and industry partners, generating leads for potential collaboration opportunities.


Photo 7a-b:ÌýÂÒÂ×Ðã’s first Advanced Therapies Symposium attracted over 250 attendees from ÂÒÂ×Ðã and beyond, including ÂÒÂ×Ðã scientists, research and clinical collaborators, funding entities, and healthcare industry leaders specialising in Advanced Therapy Medicinal Product (ATMP) research and developments.Ìý

Ìý

Read more:

• ÂÒÂ×Ðã ATMP report
• ÂÒÂ×Ðã Translational Research Office (TRO)
• ÂÒÂ×Ðã Therapeutic Innovation Networks (TINs)
  (ÂÒÂ×ÐãB)
• US regulator approves first ever gene therapy for people with haemophilia A
• New gene therapy could significantly reduce seizures in severe childhood epilepsy
• ÂÒÂ×Ðã spin out Quell Therapeutics joins forces with AstraZeneca in $2billion deal
• ÂÒÂ×Ðã spinout pioneers rare disease gene therapy to treat children with severe genetic disorders

Event speakers (In order of appearance at the event):

Session chairs and panellists:

• Professor Geraint Rees

External panellist:

Sponsors:

---

• Interested to stay informed of upcoming news, events and funding calls?

• Subscribe to our newsletterÌýand you would automatically become a member of ÂÒÂ×Ðã TINs (Therapeutic Innovation Networks) and be the first to receive our event invitations

• FollowÌýus on social media (,Ìý)Ìýand stay tuned to our news and updates.

---